Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia

Journal of Human Hypertension

Volumn 26, Issue 4, 2012, Pages 253-258

  Sifakis, S ^a   Akolekar, R ^b   Kappou, D ^a   Mantas, N ^b   Nicolaides, K H ^b,c  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

first trimester screening; insulin resistance; insulin like growth factor binding protein 3; preeclampsia; pregnancy associated plasma protein A; uterine artery Doppler

Indexed keywords

PREGNANCY ASSOCIATED PLASMA PROTEIN A; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; PREECLAMPSIA; PREMATURE LABOR; PROTEIN BLOOD LEVEL; PULSATILE FLOW; UTERINE ARTERY;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; PLACENTATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROSPECTIVE STUDIES; PULSATILE FLOW; REGRESSION ANALYSIS; UTERINE ARTERY;

EID: 84858709276     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.16     Document Type: Article

References (46)

1. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, 2002. ACOG Committee on Practice Bulletins-Obstetrics. Obstet Gynecol 2002; 99: 159-167.
2. Högberg U. 2005. The World Health Report 2005: 'make every mother and child count'-including Africans. Scand J Public Health 2005; 33: 409-411. (Pubitemid 43115054)
3. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-1059. (Pubitemid 16004866)
4. Friedman SA, Taylor RN, Roberts JM. Pathophysiology of preeclampsia. Clin Perinatol 1991; 18: 661-682.
5. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, Van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1995; 101: 669-674. (Pubitemid 24251519)
6. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005; 193: 429-436. (Pubitemid 41159538)
7. Plascencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30: 742-749. (Pubitemid 47612696)
8. Poon LCY, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH. Hypertensive disorders in pregnancy: Screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet Gynecol 2009; 34: 142-148.
9. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33: 23-33.
10. Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH, Fetal Medicine Foundation Second-Trimester Screening Group. Prediction of preeclampsia by uterine artery Doppler imaging: Relationship to gestational age at delivery and small-forgestational age. Ultrasound Obstet Gynecol 2008; 31: 310-313.
11. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. Br J Obstet Gynaecol 2006; 113: 580-589.
12. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003; 189: 1173-1177. (Pubitemid 37373917)
13. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism 1999; 48: 892-896. (Pubitemid 29310046)
14. Bosio PM, McKenna PJ, Conroy R, O'Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94: 978-984.
15. D'Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. Br J Obstet Gynaecol 2006; 113: 1264-1269. (Pubitemid 44581516)
16. Rechler MM, Clemmons DR. Regulatory actions of insulin-like growth factor-binding proteins. Trends Endocrinol Metab 1998; 9: 176-183. (Pubitemid 28328220)
17. Monzavi R, Cohen P. IGFs and IGFBPs: Role in health and disease. Best Pract Res Clin Endocrinol Metab 2002; 16: 433-447.
18. Binoux M, Hossenlopp P. Insulin-like growth factor (IGF) and IGF-binding proteins: Comparison of human serum and lymph. J Clin Endocrinol Metab 1988; 67: 509-514.
19. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 1990; 71: 797-805.
20. Lewitt MS, Saunders H, Baxter RC. Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3. Endocrinology 1993; 133: 1797-1802. (Pubitemid 23295211)
21. Giudice LC, Farrell EM, Pham H, Lamson G, Rosenfeld RG. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: Effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab 1990; 71: 806-816.
22. Bang P, Fielder PJ. Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3. Endocrinology 1997; 138: 3912-3917. (Pubitemid 27351946)
23. Milio LA, Hu J, Douglas GC. Binding of insulin-like growth factor I to human trophoblast cells during differentiation in vitro. Placenta 1994; 15: 641-651. (Pubitemid 24295070)
24. Lacey H, Haigh T, Westwood M, Aplin JD. Mesenchymally- derived insulin-like growth factor 1 provides a paracrine stimulus for trophoblast migration. BMC Dev Biol 2002; 2: 5.
25. Forbes K, Westwood M. The IGF axis and placental function. Horm Res 2008; 69: 129-137.
26. Firth SM, Baxter RC. Cellular actions of the insulinlike growth factor binding proteins. Endocr Rev 2002; 23: 824-855.
27. Han VK, Bassett N, Walton J, Challis JR. The expression of insulin-like growth factor (IGF) and IGFbinding protein (IGFBP) genes in the human placenta and membranes: Evidence for IGF-IGFBP interactions at the feto-maternal interface. J Clin Endocrinol Metab 1996; 81: 2680-2693. (Pubitemid 26240297)
28. Randhawa R, Cohen P. The role of the insulin-like growth factor system in prenatal growth. Mol Genet Metab 2005; 86: 84-90. (Pubitemid 41412163)
29. Altinkaynak K, Aksoy HH, Bakan E, Kumtepe Y. Serum IGF-I and IGFBP-3 in healthy pregnancies and patients with preeclampsia. Clin Biochem 2003; 36: 221-223. (Pubitemid 36515129)
30. Kocyigit Y, Bayhan G, Atamer A, Atamer Y. Serum levels of leptin, insulin-like growth factor-I and insulin-like growth factor binding protein-3 in women with pre-eclampsia, and their relationship to insulin resistance. Gynecol Endocrinol 2004; 18: 341-348. (Pubitemid 38916355)
31. Lewitt MS, Scott FP, Clarke NM, Wu T, Sinosich MJ, Baxter RC. Regulation of insulin-like growth factorbinding protein-3 ternary complex formation in pregnancy. J Endocrinol 1998; 159: 265-274. (Pubitemid 28520179)
32. Halhali A, Tovar AR, Torres N, Bourges H, Garabedian M, Larrea F. Preeclampsia is associated with low circulating levels of insulin-like growth factor I and 1,25-dihydroxyvitamin D in maternal and umbilical cord compartments. J Clin Endocrinol Metab 2000; 85: 1828-1833. (Pubitemid 32269284)
33. Hü binette A, Lichtenstein P, Brismar K, Vatten L, Jacobsen G, Ekbom A et al. Serum insulin-like growth factors in normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 2003; 82: 1004-1009. (Pubitemid 37311036)
34. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 31: 618-624.
35. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchaltranslucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346. (Pubitemid 28352196)
36. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV. (Pubitemid 32672922)
37. Kagan KO,Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancyassociated plasma protein-A: Impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
38. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach. Hum Hypertens 2010; 24: 104-110.
39. Toop K, Klopper A. Concentration of pregnancyassociated plasma protein-A (PAPP-A) in patients with pre-eclamptic toxaemia. Placenta 1981; 4: 167-173.
40. Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. Women with pre-eclampsia have increased serum levels of pregnancy-associated plasma protein-A (PAPP-A), inhibin A, acitivin A and soluble E-selectin. Hypertens Pregnancy 2003; 23: 45-55. (Pubitemid 36205807)
41. Khosravi J, Diamandi A, Mistry J, Krischna RG. The high molecular weight insulin-like growth factor-binding protein complex: Epitope mapping, immunoassay, and preliminary clinical evaluation. J Clin Endocrinol Metab 1999; 84: 2826-2833. (Pubitemid 30642593)
42. Lassarre C, Binoux M. Measurement of intact insulinlike growth factor-binding protein-3 in human plasma using a ligand immunofunctional assay. J Clin Endocrinol Metab 2001; 86: 1260-1266. (Pubitemid 32323014)
43. Chan SS, Twigg SM, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 (IGFBP-3) leads to insulin resistance in adipocytes. J Clin Endocrinol Metab 2005; 90: 6588-6595. (Pubitemid 41759320)
44. Kim HS, Ali O, Shim M, Lee KW, Vuguin P, Muzumdar R et al. Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr Res 2007; 61: 159-164. (Pubitemid 46146872)
45. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez- Jimenez F, Mälarstig A, Brismar K et al. IGF-I/IGFBP-3 ratio: A mechanistic insight into the metabolic syndrome. Clin Sci (Lond) 2009; 116: 507-512.
46. Ruan W, Lai M. Insulin-like growth factor binding protein: A possible marker for the metabolic syndrome? Acta Diabetol 2010; 47: 5-14.